This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the Version of Record. Please cite this article as doi: 10.1111/EJH.13436 This article is protected by copyright. All rights reserved DR. LAURA CESINI (Orcid ID : 0000-0003-4805-9928) DR. MARCO CERRANO (Orcid ID : 0000-0003-1666-3100) DR. ISABELLA CAPODANNO (Orcid ID : 0000-0002-6091-1899) DR. ROBERTO LATAGLIATA (Orcid ID : 0000-0002-7741-862X) Article type : Original Article Corresponding author email id: rob.lati@libero.it Erythropoietin Treatment in Chronic Phase Chronic Myeloid Leukemia Patients Treated with Frontline Imatinib who Developed Late Anemia Laura Cesini 1 , Camilla Frieri 2 , Claudia Baratè 3 , Federica Sorà 4 , Massimiliano Bonifacio 5 , Marco Cerrano 6 , Antonia Cagnetta 7 , Chiara Elena 8 , Lara Aprile 9 , Nicola Sgherza 10 , Malgorzata Trawinska 11 , Antonella Gozzini 12 , Isabella Capodanno 13 , Monica Crugnola 14 , Ida Carmosino 1 , Emilia Scalzulli 1 , Federica Ricci 3 , Monica Bocchia 9 , Micaela Bergamaschi 7 , Chiara Aguzzi 6 , Simona Sica 4 , Sara Galimberti 3 , Massimo Breccia 1 , Luigiana Luciano 2 , Roberto Latagliata 1 . 1 Department of Translational and Precision Medicine, University “La Sapienza” of Rome 2 Hematology, University “Federico II” of Neaples 3 Department of Clinical and Experimental Medicine – Hematology, University of Pisa 4 Hematology, Catholic University of Sacred Heart of Rome 5 Department of Medicine, Section of Hematology, University of Verona 6 Department of Oncology and Hematology, University of Turin 7 Clinical Hematology, Policlinico San Martino, Genua 8 Hematology, San Matteo Hospital, Pavia 9 Division of Hematology, University of Accepted Article